Annual Drug Patent Expirations for GLUCOPHAGE+XR Glucophage Xr is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from one supplier. There are…
The post New patent expiration for Bristol Myers drug GLUCOPHAGE X…
New patent expiration for Bristol Myers drug GLUCOPHAGE XR Read Post »
Annual Drug Patent Expirations for NIASPAN Niaspan is a drug marketed by Abbvie and is included in one NDA. It is available from eight suppliers. There is one patent protecting…
The post New patent expiration for Abbvie drug NIASPAN appeared firs…
Annual Drug Patent Expirations for GIAZO Giazo is a drug marketed by Valeant Pharms Intl and is included in one NDA. It is available from one supplier. There are five…
The post New patent expiration for Valeant Pharms drug GIAZO appeared first on…
New patent expiration for Valeant Pharms drug GIAZO Read Post »
Annual Drug Patent Expirations for PULMICORT+FLEXHALER Pulmicort Flexhaler is a drug marketed by Astrazeneca and is included in one NDA. It is available from three suppliers. There are four patents…
The post New patent expiration for Astrazeneca …
New patent expiration for Astrazeneca drug PULMICORT FLEXHALER Read Post »
Health care costs in the US touched a staggering $3.2 trillion in 2015, which makes it one of the nation’s largest industries, equaling 17.8% of gross domestic product. This translates…
The post Factors driving healthcare costs in the US appeared…
NIASPAN (niacin) Abbvie Patent: 6,469,035 Expiration: Mar 15, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit…
The post Dr…
Drug Patent Expirations for the Week of March 11, 2018 Read Post »
Annual Drug Patent Expirations for ULTIVA Ultiva is a drug marketed by Mylan Institutional and is included in one NDA. It is available from one supplier. There is one patent…
The post New patent expiration for Mylan Institutional drug ULTIVA appe…
New patent expiration for Mylan Institutional drug ULTIVA Read Post »
Annual Drug Patent Expirations for SENSIPAR Sensipar is a drug marketed by Amgen and is included in one NDA. It is available from six suppliers. There are three patents protecting…
The post New patent expiration for AMGEN drug SENSIPAR appeared f…
Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications Driven by patient loyalty, prescriber preference, pharmacist trust, and traditional marketing, branded generics&#…
Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Read Post »
As pharmaceutical companies face ceaseless pressure to expedite products to market, strategies for improving the drug development and manufacturing process gets critical. And all challenges related to drug development start…
The post Optimizing y…
Optimizing your API strategy to deliver desired results Read Post »
Get new actionable insights and updates from BiotechBlog
